3957 POINT EDEN WAY, HAYWARD, CA
Pulse Biosciences Presents nPulse™ System Data at EACTS
Material disclosure
Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
Earnings Release
Changes in Board, Management or Compensation
Reports Business Updates and First Quarter 2025 Financial Results
Q2
Q1
Amended Annual Report
FY 2024
Q3
Notice of Late Filing for Quarterly Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Prospectus Filed Pursuant to Rule 424(b)(2)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Specialized Disclosure Report
Amended Schedule 13D - Ownership Report
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload